Biotech of the week: Cell2b, the Promising Portuguese Cell Therapy Biotech

02/10/2015 - 2 minutes

As it’s a new month, we thought we would try something a little different on Labiotech.eu. Every week we are going to showcase a company of our choice found on our map. The goal is to keep everybody up to date on all the various biotech and pharma companies that are found throughout Europe. This week we will be focusing on Cell2B.

City: Lisbon, Portugal

Founded: 2011

Money raised: €1M

Employees: 10

CEO:

Mission: Cell2B is a Portuguese biotech developer for cell therapies that was founded in 2011. Their goal is to develop new therapeutic solutions for diseases that have no effective treatment, namely immune and inflammatory diseases. They mainly focus on advanced therapy medicinal products (ATMPs) and currently have two products in their pipeline, ImmuneSafe and CordSafe, with the former currently being in pre-clinical development for Graft-versus-Host Disease (GvHD).  ImmuneSafe works by modulating the immune and inflammatory responses and promoting tissue regeneration.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member